Using wearable activity monitors may eventually supplement standard assessments of performance status and functionality that could inform clinicians, especially because objective evaluation of performance status is difficult to determine.
September 2018
A National Center for Health Statistics briefing showed that liver cancer death rates increased significantly for both sexes, with death rates for men 2 to 2.5 times the rate for women from 2000 through 2016.
Faced with a persistent question from her teenage years, Elaine Chang, MD, may have come up with an answer.
Gagandeep Brar, MD, reflects on patient interactions that she has encountered throughout her fellowship.
Aditya V. Shreenivas, MD, MSCR, says a habit of continuous learning is the ideal way to stay informed about the latest data.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
5